ASSOCIATION OF ATHEROSCLEROSIS-ASSOCIATED CARDIOVASCULAR RISK FACTORS AT DIFFERENT LEVELS OF PROLACTIN IN WOMEN OF REPRODUCTIVE AGE

Objective: to study the association of prolactin with indicators of carbohydrate and lipid metabolism in women of reproductive age 25-45 years. Materials and methods: Clinical and laboratory examination of a random representative sample of women 25-45 years old. The random number method formed a sample of 416 women, who determined the level of PRL. The average age of the examined women was 36.0 ± 6.2 years. Formed a group of women who have an elevated level of PRL (prolactin> 19.5 ng/ml ( n = 95)). Statistical evaluations included a descriptive analysis of the numerical characteristics of the features (mean value, standard deviation). The studied parameters are divided into quartiles by the level of prolactin. The analysis of variance was performed using the multiple comparison method. Results: There is a decrease in the average values of fasting plasma glucose, TC, LDL in women from 1 to 4 quartile of PRL. The mean values of cholesterol-HDL increase from 1 to 3 quartile of PRL, not reaching statistical significance. BMI has minor changes between quartiles. In the group of women with a normal level of PRL with a flat analysis of the data of biochemical blood analysis, indicators of blood pressure, BMI, and waist circumference, lower levels of total cholesterol and LDL were obtained in 4 prolactin. When analyzing the studied parameters in women with a PRL level of more than 19.5 ng/ml, there is an increase in TG, BMI and waist circumference values from 1 to 4 quartile of PRL. Fasting plasma glucose TC, LDL, HDL increase from 1 to 4, however, the difference does not reach statistical significance. Conclusion: Analyzing our own and literature data, we can conclude that hyperprolactinemia can increase the risk of atherosclerotic lesions of the cardiovascular system, both through direct effects on lipids and atherosclerotic plaques, and indirectly, affecting metabolic disorders leading to obesity, development insulin resistance and changes in glucose metabolism, which in turn can affect the development of atherosclerotic lesions. The features and mechanisms of PRL effects on metabolism are very complex and need further study.

prolactin, hyperprolactinemia, atherosclerosis

1. Дзеранова Л.К., Мокрышева Н.Г., Бармина И.И., Гиниятуллина Е.Н. Метаболические эффекты пролактина // Вестн. репродукт. здоровья. 2008. № 3-4. С. 29-33.

2. Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone // Trends Endocrinol. Metab. 2006. 17. P. 110-116.

3. Freeman M.E., Kanyicska B., Lerant A., Nagy G. Prolactin: structure, function, and regulation of secretion // Physiol. Rev. 2000. Vol. 80. P. 1523-1631.

4. Serri O., Li L., Mamputu J.C., Beauchamp M.C., Maingrette F., Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy // Clin. Endocrinol. (Oxf). 2006. Vol. 64. P. 366-370.

5. Zhang L., Curhan G.C., Forman J.P. Plasma prolactin level and risk of incident hypertension in postmenopausal women // J. Hypertens. 2010. Vol. 28. P. 1400-1405.

6. Friedrich N., Schneider H.J., Spielhagen C., Markus M.R. et al. The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania // Clin. Endocrinol. (Oxf). 2011. Vol. 75. P. 561-566.

7. Friedrich N., Rosskopf D., Brabant G., Volzke H. et al. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the Study of Health in Pomerania (SHIP) // Exp. Clin. Endocrinol. Diabetes. 2010. Vol. 118. P. 266-273.

8. Haring R., Friedrich N., Volzke H., Vasan R.S. et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality // Eur. Heart J. 2014. Vol. 35. P. 1215-1221.

9. Марова Е.И., Мокрышева Н.Г., Дзеранова Л.К. Влияние гиперпролактинемии опухолевого генеза на состояние жирового обмена // Ожирение и метаболизм. 2005. № 3. С. 33-38.

10. Shanshan Shao, Zhenyu Yao. Ablation of prolactin receptor increases hepatic triglyceride accumulation // Biochem. Biophys. Res. Commun. 2018. Vol. 498. P. 693-699.

11. Pala N.A. et al. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline // Diabetol. Metab. Syndr. 2015. Vol. 7.P. 99.

12. Erem C. et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma // Clin. Endocrinol. (Oxf). 2010. Vol. 73, N 4. P. 502-507.

13. Berinder K. et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy // Pituitary. 2011. Vol. 14, N 3. P. 199-207.

14. Arslan M.S. et al. Preclinical atherosclerosis in patients with prolactinoma // Endocr. Pract. 2014. Vol. 20, N 5. P. 447-451.

15. Jiang X.B. et al. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study // Pituitary. 2014. Vol. 17, N 3. P. 232-239.

16. Ling C. et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue // J. Clin. Endocrinol. Metab. 2003. Vol. 88, N 4. P. 1804-1808.

17. Мельниченко Г.А., Рожинская Л.Я., Дзеранова Л.К. и др. Федеральные клинические рекомендации по гиперпролактинемии: клиника, диагностика, дифференциальная диагностика и методы лечения // Российская ассоциация эндокринологов. Клинические рекомендации. 2015. Москва. 19 с. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/giperprol.pdf

18. Georgiopoulos G.A., Stamatelopoulos K.S., Lambrinoudaki I. et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors // Hypertension. 2009. Vol. 54. P. 98-105.

19. Carrero J.J. et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD // Clin. J. Am. Soc. Nephrol. 2012. Vol. 7, N 2. P. 207-215.